Articles

CPhI report highlights unpredictability in CDMO growth

Flow chemistry, oncology, other aspects to grow, but the rate of change remains unclear
Written byMel J. Yeates
| 2 min read

AMSTERDAM—CPhI Worldwide, held in Frankfurt in October and organized by UBM, has announced the findings of part one of the 5th edition of the CPhI Annual Report, which focuses on immediate and long-term trends in pharmaceutical outsourcing. The unstable U.S. government administration, the longer-term implications of drug pricing and Big Pharma income repartitions are highlighted as key unknowns and risks for the contract development and manufacturing organization (CDMO) sector.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.